Zentalis Pharmaceuticals, Inc. (ZNTL)
NASDAQ (NMS) NASDAQ (NMS) Primary 
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Zentalis Pharmaceuticals, Inc. - ZNTL
NEW YORK, NY / ACCESSWIRE / July 5, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Zentalis Pharmaceuticals, Inc. ("Zentalis" or the "Company") (NASDAQ:ZNTL). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Zentalis Pharmaceuticals, Inc. - ZNTL
NEW YORK, NY / ACCESSWIRE / June 26, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Zentalis Pharmaceuticals, Inc. ("Zentalis" or the "Company") (NASDAQ:ZNTL). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Zentalis Pharmaceuticals, Inc. - ZNTL
NEW YORK, NY / ACCESSWIRE / June 21, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Zentalis Pharmaceuticals, Inc. ("Zentalis" or the "Company") (NASDAQ:ZNTL). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Zentalis (ZNTL) Tanks After FDA Puts 3 Cancer Studies on Hold
Zentalis' (ZNTL) three studies evaluating azenosertib for three different cancer indications face the FDA's partial clinical hold following the death of two patients.
Why Is Small-Cap Cancer-Focused Zentalis Pharma Stock Trading Lower On Tuesday?
Tuesday, Zentalis Pharmaceuticals Inc ZNTL announced that the FDA has placed a partial clinical hold on the following studies of azenosertib:
US FDA puts partial clinical hold on Zentalis' cancer drug studies; shares drop
Zentalis Pharmaceuticals said on Tuesday the U.S. Food and Drug Administration has placed a partial clinical hold on three studies testing its cancer drug, following the death of two trial participants.
